Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces statistically significant reductions in HbA1c and body weight in patients with type 2 diabetes and obesity, outperforming several existing antidiabetic classes including GLP-1 agonists and insulin.
Tirzepatide is a once-weekly injection that significantly lowers blood sugar and helps with weight loss in people with type 2 diabetes and obesity. It works by mimicking two natural hormones (GIP and GLP-1). Clinical trials show it is more effective than some existing diabetes medications and GLP-1 drugs alone. Common side effects include gastrointestinal issues, which are often worse at higher doses, so doctors usually start with a low dose and increase it slowly. It is not recommended for pregnant women.
This medication has demonstrated a statistically significant reduction in glycated hemoglobin in patients with diabetes and weight loss in patients with obesity and/or diabetes compared to several classes of antidiabetic drugs.
Why this rating
Based on multiple Phase III trials (SURPASS, SURMOUNT) with large sample sizes, though the paper notes limited comparisons to non-GLP-1 drugs.
Source
New class of drugs for the treatment of diabetes mellitus
A. I. Islamova et al. · Clinical Medicine (Russian Journal) · 2024
DOI 10.30629/0023-2149-2024-102-7-499-509
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →